about
Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Antiphospholipid Antibodies in Lupus Nephritis.Interferon (IFN)-λ is a potential mediator in lupus nephritisBiologics in SLE: towards new approaches.Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.Increasing Reasoning Awareness: Video Analysis of Students' Two-Party Virtual Patient Interactions.Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL.Smoking reduces the efficacy of belimumab in mucocutaneous lupusPrediction of prognosis and renal outcome in lupus nephritisThe Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus ErythematosusClinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritisEstablished organ damage reduces belimumab efficacy in systemic lupus erythematosusALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosusHow to use the Lupus Low Disease Activity State (LLDAS) in clinical trialsPredictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosusAutoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus ErythematosusUse of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
P50
Q35008162-3861267C-39BC-4178-AD1A-46AD0860132BQ36060060-FDD98F42-73DF-4793-A0D2-479F3FC2848AQ37464013-97B3F770-FF86-44D9-830E-868DA5B648F1Q38163140-4A8E6D51-2B03-4D1B-84E4-D0C66CAB3A70Q39101016-61210DB6-C581-4829-9AD1-6E9A49F57D9AQ39143034-A9864E78-CD18-4B7C-9EC4-9F514D73FDF9Q50421645-B5734A49-E161-49CF-A176-D37F719E7E89Q54203979-BE02336F-6FFE-4F8A-A9B5-2A2D8F79FDD0Q89351208-60EA05DC-0274-4F6B-AF33-67B73B4418B9Q90177663-A311AF3F-4C22-4636-84FE-DCB85EEC6A22Q90585211-19E482CE-D0D3-46A5-A640-31D629DC5230Q90671191-EDB3A0D8-28F3-4764-84FF-419EDAA326EAQ90710495-22DAFD54-77F1-4F14-96D4-C32BA9BF8981Q90891574-B11DD8F7-E989-4C92-8BA1-054775056CD2Q91269794-6194FB2A-B9D5-4DB1-8091-DD35BFB73000Q91928547-A3B9C4B0-3831-4EB4-B230-2CCCDB20B8CAQ92485957-4E7829DC-590E-41E6-932A-7D6AAF477DB7Q95304723-C924C564-9EE4-46FC-9B2C-BF19136EE5FEQ96345626-1C956FB2-E682-4F9F-A4A1-25DD8D82D8D2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
I Parodis
@ast
I Parodis
@en
I Parodis
@es
I Parodis
@nl
type
label
I Parodis
@ast
I Parodis
@en
I Parodis
@es
I Parodis
@nl
prefLabel
I Parodis
@ast
I Parodis
@en
I Parodis
@es
I Parodis
@nl
P106
P31
P496
0000-0002-4875-5395